STAAR Surgical's (NASDAQ:STAA) Direction, Growth Looks Positive

Based on their headway in Japan, Benchmark like the potential growth of STAAR Surgical (NASDAQ:STAA), and believes management is taking them in a good direction.

The Japanese have already approved STAAR's ICL lense in the early part of 2010, and it appears Toric should be approved by the end of 2011.

Benchmark noted that, "however, under Japanese regulations surgeons may apply for a special exemption in order to implant lenses that are approved for sales in other countries. We believe this could offer substantial refractive ICL and Toric opportunity in Japan this year."

Also in the pipeline is STAAR’s preloaded silicone IOL 510(k) application for cataract surgery, which the company is seeking approval of from the FDA, which could happen soon, says Benchmark.

Benchmark reiterates their "Buy" rating on STAAR, which closed Wednesday at $6.41, up $0.06, or 0.94 percent. Benchmark increased their price target on STAAR from $6 to $10.